olaparib maintenance after platinum response: polo data

Q: olaparib maintenance after platinum response: polo data

Summary In patients with germline BRCA1/2-mutated metastatic pancreatic cancer who have not progressed during first-line platinum-based chemotherapy, maintenance olaparib significantly improves progression-free survival compared to placebo (HR 0.53; median PFS 7.4 vs. 3.8 months) [1]. However, an interim analysis of overall survival showed no significant difference between the groups (median OS 18.9 vs. 18.1 months; HR 0.91) [1]. Evidence Trial: POLO trial (NCT02184195), a randomized, double-blind, placebo-controlled phase 3 study published in *The New England Journal of Medicine* [1]. Population: Patients with germline BRCA1 or BRCA2 mutations and metastatic pancreatic cancer whose disease had not progressed during first-line platinum-based chemotherapy [1]. Intervention: Maintenance olaparib (300 mg twice daily) versus placebo in a 3:2 randomization ratio [1]. Primary Endpoint: Progression-free survival assessed by blinded independent central review [1]. Key Results: Median PFS was 7.4 months for olaparib vs. 3.8 months for placebo (HR 0.53; 95% CI, 0.35 to 0.82; P = 0.004) [1]. Secondary Results: Interim overall survival analysis (46% data maturity) showed median OS of 18.9 months for olaparib vs. 18.1 months for placebo (HR 0.91; 95% CI, 0.56 to 1.46; P = 0.68) [1]. Safety: Grade ≥3 adverse events occurred in 40% of the olaparib group vs. 23% of the placebo group; discontinuation due to adverse events was 5% vs. 2%, respectively [1]. Caveats The overall survival benefit was not demonstrated in this interim analysis, and the data maturity was only 46% at the time of reporting [1]. The study population was strictly limited to patients with germline BRCA1/2 mutations who had achieved disease control on prior platinum therapy, limiting generalizability to the broader metastatic pancreatic cancer population [1].

Question

Accepted Answer

Summary

In patients with germline BRCA1/2-mutated metastatic pancreatic cancer who have not progressed during first-line platinum-based chemotherapy, maintenance olaparib significantly improves progression-free survival compared to placebo (HR 0.53; median PFS 7.4 vs. 3.8 months) [1]. However, an interim analysis of overall survival showed no significant difference between the groups (median OS 18.9 vs. 18.1 months; HR 0.91) [1].

Evidence

Trial: POLO trial (NCT02184195), a randomized, double-blind, placebo-controlled phase 3 study published in *The New England Journal of Medicine* [1].

Population: Patients with germline BRCA1 or BRCA2 mutations and metastatic pancreatic cancer whose disease had not progressed during first-line platinum-based chemotherapy [1].

Intervention: Maintenance olaparib (300 mg twice daily) versus placebo in a 3:2 randomization ratio [1].

Primary Endpoint: Progression-free survival assessed by blinded independent central review [1].

Key Results: Median PFS was 7.4 months for olaparib vs. 3.8 months for placebo (HR 0.53; 95% CI, 0.35 to 0.82; P = 0.004) [1].

Secondary Results: Interim overall survival analysis (46% data maturity) showed median OS of 18.9 months for olaparib vs. 18.1 months for placebo (HR 0.91; 95% CI, 0.56 to 1.46; P = 0.68) [1].

Safety: Grade ≥3 adverse events occurred in 40% of the olaparib group vs. 23% of the placebo group; discontinuation due to adverse events was 5% vs. 2%, respectively [1].

Caveats

The overall survival benefit was not demonstrated in this interim analysis, and the data maturity was only 46% at the time of reporting [1]. The study population was strictly limited to patients with germline BRCA1/2 mutations who had achieved disease control on prior platinum therapy, limiting generalizability to the broader metastatic pancreatic cancer population [1].